PTGS1

Prostaglandin G/H synthase 1 · P23219 · PTGS1 on Sugi Atlas →

652,490 patent compounds predicted against PTGS1, 419,767 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Celecoxib (SCHEMBL3708)	1.00	10/20
Etoricoxib (SCHEMBL4680)	1.00	10/20
Rofecoxib (SCHEMBL3050)	1.00	9/20
SCHEMBL594	0.45	9/20
SCHEMBL3418	0.62	8/20
Ketoprofen (SCHEMBL2896)	1.00	6/20
Resveratrol (SCHEMBL19425)	1.00	6/20
Resveratrol (SCHEMBL19426)	1.00	6/20
Ibuprofen (SCHEMBL3001)	1.00	5/20
Fenoprofen (SCHEMBL3797)	1.00	5/20
R-Fenoprofen (SCHEMBL4082)	1.00	5/20
Fiboflapon (SCHEMBL11820)	1.00	5/20
Piroxicam (SCHEMBL13462)	1.00	5/20
Epigallocatechin (SCHEMBL19553)	1.00	5/20
Icosapent (SCHEMBL20469)	1.00	5/20
Fenoprofen (SCHEMBL4081)	0.97	5/20
Doconexent (SCHEMBL19577)	0.77	5/20
Theaflavin (SCHEMBL19551)	0.67	5/20
Theaflavin (SCHEMBL19552)	0.63	5/20
Tretinoin (SCHEMBL3145)	1.00	4/20

Clinical trials — most relevant to PTGS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes	PHASE4	UNKNOWN
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)	PHASE4	COMPLETED
Type 2 Diabetes Mellitus and Atherosclerosis	PHASE4	UNKNOWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
Effect of Selective COX-2 Inhibition on Ulcer Healing	PHASE3	COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	PHASE3	COMPLETED
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial	PHASE3	UNKNOWN
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial	PHASE3	UNKNOWN
Celebrex for Pain Relief After Oral Surgery	PHASE2	COMPLETED
Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis /Bladder Pain Syndrome	PHASE2	UNKNOWN
Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus	PHASE2	UNKNOWN
Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury	PHASE2	WITHDRAWN
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction	PHASE2	COMPLETED
Pathways of Eicosanoid Metabolism	EARLY_PHASE1	ENROLLING_BY_INVITATION
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
OrthoCor Advanced Trial for Knee Osteoarthritis	nan	COMPLETED
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease	nan	COMPLETED
Effect of Perioperative IV Ibuprofen on Cerebral Oxygenation and Postoperative Cognition During One-Lung Ventilation	nan	NOT_YET_RECRUITING
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis	nan	UNKNOWN
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn	nan	RECRUITING
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN
Palmitoylethanolamide in Ulcerative Colitis	nan	NOT_YET_RECRUITING
Cyclooxygenase Levels Following Surgery to Remove Third Molars (Wisdom Teeth)	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTGS1 binder may also engage these)

Protein	Name	Similarity
O62664	—	1.000	O62664 →
P05979	—	1.000	P05979 →
Q8HZR1	—	1.000	Q8HZR1 →
Q63921	—	1.000	Q63921 →
Q05769	—	1.000	Q05769 →
O97554	—	1.000	O97554 →
O62698	—	1.000	O62698 →
P22437	—	1.000	P22437 →
P79208	—	0.998	P79208 →
PTGS2	Prostaglandin G/H synthase 2	0.998	landscape →
O19183	—	0.995	O19183 →
O02768	—	0.994	O02768 →
P27607	—	0.994	P27607 →
O62725	—	0.992	O62725 →
P35355	—	0.990	P35355 →
P70682	—	0.989	P70682 →
O61213	—	0.985	O61213 →
P82600	—	0.983	P82600 →
P40126	—	0.981	P40126 →
P29812	—	0.980	P29812 →
O93505	—	0.979	O93505 →
Q9VEG6	—	0.978	Q9VEG6 →
Q4R1H1	—	0.977	Q4R1H1 →
G4N4J5	—	0.977	G4N4J5 →
P07147	—	0.977	P07147 →
P81732	—	0.976	P81732 →
Q2VPW6	—	0.976	Q2VPW6 →
Q4WY82	—	0.976	Q4WY82 →
P35419	—	0.976	P35419 →
P12031	—	0.976	P12031 →